Table 5.
Univariate and multivariate analysis for clinical outcome, microbiological outcome, and mortality in FDA-approved vs. off-label indications.
| Variables | Univariate model | Adjusted multivariate model* | |||
|---|---|---|---|---|---|
| FDA-approved indications (n = 29) | Off-label indications (n = 124) | P | Odds ratio (95 % confidence interval) | P | |
| Clinical | |||||
| Outcome | |||||
| Success | 16 (64%) | 43 (38.7%) | 0.02 | 1.65 (0.60–4.49) | 0.33 |
| Failure | 9 (36%) | 68 (61.3%) | |||
| Microbiological Outcome |
|||||
| Success | 6 (50%) | 20 (16.1%) | 0.58 | 1.07 (0.38–2.97) | 0.90 |
| Failure | 6 (50%) | 104 (83.9%) | |||
| Total mortality | 5 (17.2%) | 64 (51.6%) | 0.001 | 4.00 (1.30–12.31) | 0.01 |
| 7 days post-treatment mortality | 3 (10.3%) | 48 (38.7%) | 0.004 | 3.50 (0.97–12.61) | 0.05 |
| In-hospital mortality | 2 (6.9%) | 16 (12.9%) | 0.53 | 2.00 (0.43–9.23) | 0.37 |
Potentially confounding variables controlled for in the adjusted model
*
were: cardiovascular disease, vasopressors given before or ≤ 24 h of tigecycline therapy, hemodynamic failure, mechanical ventilation, treatment strategy, monotherapy, and combination therapy.